Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Vassiliki Papadimitrakopoulou"'
Autor:
Xinyi Zhang, Frederico O. Gleber‐Netto, Shidan Wang, Roberta Rayra Martins‐Chaves, Ricardo Santiago Gomez, Nadarajah Vigneswaran, Arunangshu Sarkar, William N. William Jr, Vassiliki Papadimitrakopoulou, Michelle Williams, Diana Bell, Doreen Palsgrove, Justin Bishop, John V. Heymach, Ann M. Gillenwater, Jeffrey N. Myers, Renata Ferrarotto, Scott M. Lippman, Curtis Rg Pickering, Guanghua Xiao
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7508-7518 (2023)
Abstract Background Oral leukoplakia (OL) is associated with an increased risk for oral cancer (OC) development. Prediction of OL cancer progression may contribute to decreased OC morbidity and mortality by favoring early intervention. Current OL pro
Externí odkaz:
https://doaj.org/article/f1684d19b6ad4c94aa6119b3cd2b7657
Autor:
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCL
Externí odkaz:
https://doaj.org/article/97023c9e42e0450eab3688b9d4689761
Autor:
Omar Alhalabi, Jianfeng Chen, Yuxue Zhang, Yang Lu, Qi Wang, Sumankalai Ramachandran, Rebecca Slack Tidwell, Guangchun Han, Xinmiao Yan, Jieru Meng, Ruiping Wang, Anh G. Hoang, Wei-Lien Wang, Jian Song, Lidia Lopez, Alex Andreev-Drakhlin, Arlene Siefker-Radtke, Xinqiao Zhang, William F. Benedict, Amishi Y. Shah, Jennifer Wang, Pavlos Msaouel, Miao Zhang, Charles C. Guo, Bogdan Czerniak, Carmen Behrens, Luisa Soto, Vassiliki Papadimitrakopoulou, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Jack Roth, Stephen Swisher, Ignacio Wistuba, John Heymach, Jing Wang, Matthew T. Campbell, Eleni Efstathiou, Mark Titus, Christopher J. Logothetis, Thai H. Ho, Jianjun Zhang, Linghua Wang, Jianjun Gao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
The deficiency of MTAP, an enzyme of the adenine salvage pathway, occurs in some cancers. Here the authors perform a small cohort phase II clinical trial with metastatic MTAP-deficient urothelial cancer (UC) and show an increased overall response whe
Externí odkaz:
https://doaj.org/article/7a4eb434bab9460784c2152084c1035e
Autor:
Jianhua Zhang, Hao Xu, Alexandre Reuben, Brian Alexander, Jack Lee, Tina Cascone, Jianjun Zhang, Kyle G Mitchell, Marcelo V Negrao, Stephen G Swisher, John V Heymach, Don L Gibbons, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Anne Tsao, Chang-Jiun Wu, Vincent A Miller, Bonnie S Glisson, Karthikeyan Murugesan, Meagan Montesion, Garrett Frampton, Katja Schulze, Ilze Bara, Vincent Shen, Sylvia Hu, Dawen Sui, Michael E Goldberg, David S Barreto, Jacqulyne P Robichaux, Carl M Gay, Lingzhi Hong, Waree Rinsurongkawong, Vassiliki Papadimitrakopoulou, Gaurav Singal, Lee A Albacker, David Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. W
Externí odkaz:
https://doaj.org/article/deb634044c5641f5a4d7746a8b39b598
Publikováno v:
Journal of Personalized Medicine, Vol 4, Iss 3, Pp 386-401 (2014)
The approval of EGFR and ALK directed tyrosine kinase inhibitors materialized the concept of tailoring therapy on the basis of specific biomarkers for treating patients with NSCLC. Research for other biologics, although demonstrating clinical benefit
Externí odkaz:
https://doaj.org/article/18d3ca866e1b47daa0f9750b50837fdd
Autor:
Jieru Meng, Bingbing Dai, Bingliang Fang, B Nebiyou Bekele, William G Bornmann, Duoli Sun, Zhenghong Peng, Roy S Herbst, Vassiliki Papadimitrakopoulou, John D Minna, Michael Peyton, Jack A Roth
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e14124 (2010)
AZD6244 and MK2206 are targeted small-molecule drugs that inhibit MEK and AKT respectively. The efficacy of this combination in lung cancer is unknown. Our previous work showed the importance of activated AKT in mediating resistance of non-small cell
Externí odkaz:
https://doaj.org/article/5a2c9bf45d224b3b8e13b8bd8bb0bb5d
Autor:
Edward B. Garon, Alexander I. Spira, Sarah B. Goldberg, Jamie E. Chaft, Vassiliki Papadimitrakopoulou, Tina Cascone, Scott J. Antonia, Julie R. Brahmer, D. Ross Camidge, John D. Powderly, Antoinette J. Wozniak, Enriqueta Felip, Song Wu, Maria L. Ascierto, Nairouz Elgeioushi, Mark M. Awad
Publikováno v:
Journal of Thoracic Oncology.
Autor:
Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan Faller, Tareq Al Baghdadi, Susan Hines, Leah Everhart, Louise Highleyman, Vassiliki Papadimitrakopoulou, Joel W. Neal, Saiama N. Waqar, Jyoti D. Patel, Jhanelle E. Gray, David R. Gandara, Karen Kelly, Roy S. Herbst
Publikováno v:
J Clin Oncol
PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising resul
Autor:
Daniel C. Cho, Michael E. Hurwitz, Chantale Bernatchez, Yijie Liao, Ernesto Iacucci, Ahsan Rizwan, Christie Fanton, Sandra Aung, Ute Hoch, Alison L. Hannah, Jonathan Zalevsky, Mary A. Tagliaferri, Brendan D. Curti, Scott S. Tykodi, Mario Sznol, Scott N. Gettinger, Harriet M. Kluger, Cara Haymaker, Vassiliki Papadimitrakopoulou, Patrick Hwu, Salah-Eddine Bentebibel, Nizar M. Tannir, Adi Diab
This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (melanoma, re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76d9b8ad447190ee9c1740fd458386d6
https://doi.org/10.1158/2159-8290.c.6547937.v1
https://doi.org/10.1158/2159-8290.c.6547937.v1
Autor:
Daniel C. Cho, Michael E. Hurwitz, Chantale Bernatchez, Yijie Liao, Ernesto Iacucci, Ahsan Rizwan, Christie Fanton, Sandra Aung, Ute Hoch, Alison L. Hannah, Jonathan Zalevsky, Mary A. Tagliaferri, Brendan D. Curti, Scott S. Tykodi, Mario Sznol, Scott N. Gettinger, Harriet M. Kluger, Cara Haymaker, Vassiliki Papadimitrakopoulou, Patrick Hwu, Salah-Eddine Bentebibel, Nizar M. Tannir, Adi Diab
Consolidated supplementary appendix: tables, figures, text plus legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18296821a0fd4a3f57f085659726850a
https://doi.org/10.1158/2159-8290.22535747.v1
https://doi.org/10.1158/2159-8290.22535747.v1